Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-5219 in acute or chronic gastritis
NCT06151210Phase 3Completed
- Sponsor
- Dong-A ST
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of DA-5219 in acute gastritis and chronic gastritis (2 arms), sponsored by Dong-A ST. Primary endpoint: Improvement rate of gastric mucosal erosion at 2 weeks. Started Jan 2024; status: completed.
02
Drugs
DA-5219
03
Conditions
acute gastritischronic gastritis
Beyond the preview
Go deeper on NCT06151210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06151210.